COST–EFFECTIVENESS ANALYSIS OF THE MONTELUKAST APPLICATION IN CHILDREN WITH BRONCHIAL ASTHM IN THE CONDITIONS OF THE REPUBLIC OF BELARUS HEALTH CARE SYSTEM
https://doi.org/10.15690/pf.v9i5.449
Abstract
The aim of this study was to estimate the montelukast cost-effectiveness in children with mild and moderate persistent asthma in Belarus. Patients and methods. A one-year decision tree model of asthma for a hypothetical cohort of 100 children with asthma and a lack of basic therapy or taking either montelukast or inhaled glucocorticosteroids has been constructed on the basis of the results of randomized clinical studies and local data. Results. In children older than 6 years of age the CER of fluticasone application was $1.45 per «day without asthma attacks, exacerbations, use of short-acting β2-receptor agonists» as compared to the montelukast CER — $2.62. In 2–6-year-old children the CER of montelukast application was $4.1, the budesonide inhalation suspension CER — $5.6, the CER of the lack of basis therapy — $6.9. Conclusion. The use of oral montelukast is considered to be cost-effective in 2–6-year-old children with mild and moderate persistent asthma as compared to the budesonide inhalation suspension or lack of basis therapy in the Republic of Belarus. Inhaled glucocorticosteroids is the priority medicine in children older than 6 years of age who are able to master the inhalation technique.
About the Authors
I. N. Kozhanova
Belarussian State Medical University, Minsk, Belarus
Belarus
Belarus
I. S. Romanova
Belarussian State Medical University, Minsk, Belarus
Belarus
Belarus
L. N. Gavrilenko
Belarussian State Medical University, Minsk, Belarus
Belarus
Belarus
A. A. Chmyreva
Republican Center for Medical Technologies, Computer Systems, Administration and Management of Health, Minsk, Belarus
Belarus
Belarus
М. М. Sachek
Republican Center for Medical Technologies, Computer Systems, Administration and Management of Health, Minsk, Belarus
Belarus
Belarus
References
1. Клинические протоколы диагностики и лечения БА. Утверждены МЗ РБ № 122 от 23.02.2006.
2. GINA. Revised 2011. 124 p. Available at: www.ginasthma.org
3. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Revised 2008. 28 p. Available at: www.ginasthma.org
4. Hay D. W. Pharmacology of leukotriene recepor antagonists: more than inhibitors of bronchoconstriction. Chest. 1997; 111 (Suppl. 2): 35–45.
5. Lipworth B. J. Leukotriene-receptor antagonists. Lancet. 1999; 353: 57–62.
6. ISAAC. The international study of asthma and allergies in childhood. Available at: www.isaac.auckland.ac.nz/index.html
7. World Health Organization. WHO factsheet 206: bronchial asthma. Available at: www.who.int/mediacentre/factsheets/fs206/en
8. Аллергия у детей: от теории к практике. Под ред. Л.С. Намазовой-Барановой. 2011. Союз педиатров России. 668 с.
9. Lenney W. The burden of pediatric asthma. Pediatr pulmonol. 1997; 15: 13–16.
10. Давидовская Е. И. Бронхиальная астма сегодня — проблемы и решения. URL: http://www.belmapo.by/page/5/355
11. Скепьян Е. Н. Бронхиальная гиперреактивность на фоне физической нагрузки и ее коррекция у детей с бронхиальной астмой. Автореф. диссертации на соискание ученой степени кандидата медицинских наук по специальности 14.00.09 Педиатрия. Минск. 2009.
12. Drazen M. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999; 340: 197–206.
13. Garcia M. L. Montelukast, com pared with fluticasone, for control of asthma among 6 to 14 year old patients with mild asthma: the MOSAIC study. Pediatrics. 2005; 116 (2): 360–369.
14. Jonas D. E. et al. Drug class review: controller medications for asthma. Final update 1 report [Internet]. Portland (OR): oregon health & science university. 2011 April. Available at: http://www.ncbi.nlm.nih.gov/books/n/cmasthma11/
15. Knorr B. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001; 108: 48.
16. Sorkness C. A. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007; 119 (1): 64–72.
17. Szefler S. J. Long-term inhaled corticosteroids in preschool children at high risk for asthma. J Allergy Clin Immunol. 2007; 120 (5): 1043–1050.
18. Ягудина Р. И., Куликов А. Ю., Комаров И. А. Методология проведения анализа «затрат» при проведении фармакоэкономических исследований. Фармакоэкономика. 2011; 4 (3).
19. Среднее число дней занятости койки, среднее число дней пребывания больного на койке, оборот койки и больничная летальность. URL: http://minzdrav.by/med/docs/stat/Tabl11_2_2009-2008.doc
20. Кобякова О. С. Эффективность оказания медицинской помощи больным бронхиальной астмой на территории Томской области. Бюллетень сибирской медицины. 2011; 1: 174–178.
21. Клименко В. А. Вирус-индуцированная бронхиальная астма у детей: состояние проблемы и пути решения. Астма та алергiя. 2011; 4: 50–57.
22. Ростова А. В. Роль комплексной терапии детей с бронхиальной астмой в достижении контроля течения заболевания. Аллергология. 2006; 3: 41–44.
23. Валовой внутренний продукт. URL: http://www.belstat.gov.by/homep/ru/indicators/gross.php
24. Национальный банк Республики Беларусь. URL: http://www.nbrb.by/
Review
For citations:
Kozhanova I.N., Romanova I.S., Gavrilenko L.N., Chmyreva A.A., Sachek М.М. COST–EFFECTIVENESS ANALYSIS OF THE MONTELUKAST APPLICATION IN CHILDREN WITH BRONCHIAL ASTHM IN THE CONDITIONS OF THE REPUBLIC OF BELARUS HEALTH CARE SYSTEM. Pediatric pharmacology. 2012;9(5):8-13. (In Russ.) https://doi.org/10.15690/pf.v9i5.449
Views:
746
Email this article 